Drugs / PegLiposomal Doxorubicin
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04358341 | Jun 2020 → Jun 2022 | gastric cancer | Sixth Affiliated Hospital, Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT00815945 | Jun 2008 → Nov 2011 | carcinosarcoma, leiomyosarcoma | AGO Study Group | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PegLiposomal Doxorubicin | “However, traditional anthracyclines are more cardiotoxic; and (Pegliposomal Doxorubicin) PLD, as a new liposome dosage form of doxorubicin, has better cardiac safety.” NCT04358341 ↗ |
| Route | Intravenous | “PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months” NCT00815945 ↗ |